The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.67 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.26 — no flag raisedOK
- Earnings quality 91/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as JOHNSON & JOHNSON reports it. History and quarterly detail are in the app.
- Innovative Medicine$60.4B
- MedTech$33.8B
- Pharmaceutical$670.0M
Leadership changes
From JOHNSON & JOHNSON's own filings, the day they're filed.
- Daniel Pinto · director · appointmenteff. 2025-07-01
- Peter M. Fasolo · President · departureeff. 2024-10-01
- Ashley McEvoy · President · departureeff. 2023-10-20
Latest filings
- 8-K · Company announcement2026-04-28
- 10-Q · Quarterly report2026-04-22
- 8-K · Company announcement2026-04-14
- DEF 14A · Annual proxy (pay & governance)2026-03-11
- 10-K · Annual report2026-02-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about JOHNSON & JOHNSON, every answer cited🔒
- The Intelligence Brief — added when JOHNSON & JOHNSON's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.